Immunocytokines

Immunocytokines Market by Indication (Cervical Cancer, Cholangiocarcinoma, Esophageal Cancer, Gallbladder Cancer, Head & Neck Cancer, Melanoma, Non-Small Cell Lung Cancer, Rheumatoid Arthritis, Soft Tissue Sarcoma), Route of Administration (Intravenous, Intratumoral, Subcutaneous), and Key Geographical Regions (US, Canada, Germany, UK, France, Italy, Spain, China, Japan, South Korea, Australia, Australia, Brazil, Argentina, Israel, Turkey): Industry Trends and Global Forecasts, 2021-2030

  • Lowest Price Guaranteed From USD 5,899

  • Published
    January 2021

  • Pages
    205

  • View Count
    4866

  • Buy Now

Example Insights

Immunocytokines-Market-Context Immunocytokines-Market-Pipeline Immunocytokines-Market-Distribution-by-Type-of-Cytokine
Immunocytokines-Market-Partnerships-and-Funding Immunocytokines-Market-Clinical-Research-Landscape Immunocytokines-Market-Mapping-Key-Opinion-Leaders
Immunocytokines-Market-Opportunity    

 

Overview

Cancer is one of the leading causes of death worldwide, accounting for an estimated 0.6 million deaths in 2020, in the US alone. The World Health Organization has estimated the number of new cancer cases to rise by 70%, worldwide, over the next 20 years. It is a well-known fact that the conventional treatment options, such as chemotherapy, radiation therapy, and surgery, demonstrate limited efficacy in late-stage cancers. Moreover, the non-specific and highly toxic nature of traditional chemotherapy and radiation therapy, have been demonstrated to have detrimental effects on patients’ quality of life. Amongst the emerging class of targeted anti-cancer therapies, immunotherapy has emerged as a versatile option, having demonstrated the capability to selectively target and eliminate tumor cells. As a result, such products have favorable side effects profiles. For instance, immune check point inhibitors (such as atezolizumab, nivolumab, and pembrolizumab) have been demonstrated to offer long term clinical benefits to patients suffering from metastatic tumors. Similarly, other immunotherapies, such as dendritic cell therapy, T cell receptor transduced T cells, and chimeric antigen receptor (CAR)-modified T cells have shown promising results in eradicating primary and metastasized cancer cells. However, these therapies have been associated with severe and often life-threatening side effects, such as cytokine storm. Moreover, for T-cell therapies, mispairing of endogenous and transfected TCR α and β chains have been demonstrated to have detrimental biological effects. 

Traditionally, cytokines have been investigated as a therapeutic modality across multiple clinical trials, particularly as anti-cancer agents. However, the systemic administration of such potent, biologically-active molecules has been shown to be associated with a wide range of dose-dependent side effects and unfavorable pharmacokinetic properties, which, in a way, hinders dose escalation to therapeutically beneficial levels. To overcome the treatment-limiting toxicities of cytokines, researchers are now focusing on immunocytokines. Immunocytokines are fusion proteins, featuring the target specificity of antibodies and the immunological response mediating capabilities of specific cytokines. These engineered pharmacologically-active molecules have, so far, demonstrated better efficacy and reduced toxicity compared to conventional cytokine-based therapies. As a result, immunocytokines are now being investigated for the treatment of a wide array of target indications, including cancers, autoimmune disorders, and certain chronic inflammatory diseases. It is also worth highlighting that this upcoming class of molecules has been demonstrated to work in synergy with certain other established therapeutics, including small molecule drugs (doxorubicin and cytarabine), intact antibodies (atezolizumab, durvalumab, ipilimumab, and nivolumab), radiation therapy, and other immunocytokines. Driven by encouraging clinical trial results, this niche, but emerging domain, is poised to witness healthy growth over the next decade, with pioneers in the field likely to benefit from the first-to-market advantage.

Scope of the Report

The “Immunocytokines Market, 2020-2030” report features an extensive study of the current and future potential of immunocytokines being developed for the treatment of rheumatoid arthritis and various types of cancer. In addition, it features an elaborate discussion on the likely opportunity for the players engaged in this domain, over the next decade. Amongst other elements, the report includes:

  • A detailed review of the current market landscape of immunocytokines, providing information on phase of development (phase III, phase II / III, phase II, phase I / II, phase I, and discovery / preclinical stage) of lead candidates, type of therapy (monotherapy and combination therapy), type of cytokine used (IL, IFN, TGF-β, TNF, and others), type of antibody used (anti-CD20, anti-CEA, anti-CTLA-4, anti-DNA, anti-EDA, anti-EDB, anti-FAP, anti-GC2, anti-Her2, anti-KS, anti-PD-L1, anti-PD-1, anti-TA-MUC1, and anti-Tenascin-C), target disease indications (blood cancer, brain cancer, breast cancer, gastrointestinal cancer, gynecological cancer, head and neck cancer, lung cancer, prostate cancer, renal cancer, rheumatoid arthritis, skin cancer, undisclosed solid tumors, and others), and route of administration (intravenous, intratumoral, subcutaneous, and others). In addition, the report presents the details of the companies developing these immunocytokines, including information on year of establishment, company size, and location of headquarters.
  • Tabulated profiles of prominent immunocytokine developers. Each profile features a brief overview of the company, its financial information (if available), product portfolio, recent developments, and an informed future outlook.
  • An analysis of recent developments in the field of immunocytokines. It includes partnerships inked by various stakeholders in this domain, during the period between January 2016 and October 2020, covering clinical trial agreements, licensing agreements, mergers and acquisitions, research agreements, research and development agreements, and others. In addition, the report features an analysis of the investments made, including debt funding, equity, venture capital financing, capital raised from IPOs and subsequent offerings, at various stages of development, in companies that are focused on developing immunocytokines.
  • An in-depth analysis of completed, ongoing, and planned clinical studies of various immunocytokines, based on various relevant parameters, such as trial registration year, phase of development, current trial status, enrolled patient population, study design, leading industry players (in terms of number of trials conducted), study focus, target disease indication, and key geographical regions.
  • A list of key opinion leaders (KOLs) within this domain, and detailed 2×2 matrices to assess the relative experience of key individuals who were shortlisted based on their contribution (in terms of involvement in various clinical studies) to this field. It also includes a schematic world map representation (highlighting the geographical locations of eminent scientists / researchers) and an analysis evaluating the (relative) level of expertise of different KOLs, based on number of publications, number of citations, participation in clinical trials, number of affiliations, and strength of professional network (based on information available on LinkedIn).

One of the key objectives of the report was to estimate the existing market size and potential future growth opportunities. Based on various parameters, such as disease prevalence, anticipated adoption of immunocytokines, and the likely selling price of such therapeutic products, we have provided informed estimates on the evolution of the market for the period 2020-2030. The report also features the likely distribution of the current and forecasted opportunity across [A] target disease indications (cervical cancer, cholangiocarcinoma, esophageal cancer, gallbladder cancer, head and neck cancer, melanoma, non-small cell lung cancer, rheumatoid arthritis, and soft tissue sarcoma), [B] routes of administration (intravenous, intratumoral, and subcutaneous), and [C] key geographical regions (US, Canada, Germany, UK, France, Italy, Spain, China, Japan, South Korea, Australia, Brazil, Argentina, Israel, and Turkey). In order to account for future uncertainties and to add robustness to our model, we have provided three market forecast scenarios, namely conservative, base, and optimistic scenarios, representing different tracks of the industry’s growth.

The opinions and insights presented in the report were influenced by discussions held with senior stakeholders in the industry. The report features detailed transcripts of interviews held with the following industry stakeholders:

  • Stephen Gillies, President and CEO, Provenance Biopharmaceuticals
  • Patrik Kehler, Senior Director Scientific and Business Development, Glycotope

All actual figures have been sourced and analyzed from publicly available information forums and primary research discussions. Financial figures mentioned in this report are in USD, unless otherwise specified.

Key Questions Answered

  • Who are the leading players engaged in the development of immunocytokines?
  • Which cancer indications can be treated with immunocytokines?
  • Which partnership models are commonly adopted by stakeholders engaged in this domain?
  • What are the investment trends in this industry?
  • Which are the most active clinical trial centers?
  • Who are the key opinion leaders that can help you drive your development efforts?
  • How is the current and future market opportunity likely to be distributed across key market segments?

Contents

Chapter Outlines

Chapter 2 is an executive summary of the insights captured in our research. It offers a high-level view on the current state of the market for immunocytokines and its likely evolution in the short-mid-term and long term.

Chapter 3 provides an introduction to immunocytokines, featuring brief descriptions of cytokines that are used for the treatment of oncological disorders. It also includes a discussion on the advent and evolution of engineered cytokines. The chapter lays emphasis on the advantages of engineered cytokines, including immunocytokines, and provides details on the strategies for the development of such therapies. It also features a brief discussion on the opportunities and the likely future trends in this field. 

Chapter 4 provides information on over 75 immunocytokines that are currently under development for the treatment of rheumatoid arthritis and various cancer indications. It features a detailed analysis of pipeline molecules, based on phase of development (phase III, phase II / III, phase II, phase I / II, phase I, and discovery / preclinical stage) of lead candidates, type of therapy (monotherapy and combination therapy), type of cytokine used (IL, IFN, TGF-β, TNF, and others), type of antibody used (anti-CD20, anti-CEA, anti-CTLA-4, anti-DNA, anti-EDA, anti-EDB, anti-FAP, anti-GC2, anti-Her2, anti-KS, anti-PD-L1, anti-PD-1, anti-TA-MUC1, and anti-Tenascin-C), target disease indications (blood cancer, brain cancer, breast cancer, gastrointestinal cancer, gynecological cancer, head and neck cancer, lung cancer, prostate cancer, renal cancer, rheumatoid arthritis, skin cancer, undisclosed solid tumors, and others), and route of administration (intravenous, intratumoral, subcutaneous, and others). In addition, the chapter includes details of the companies developing these immunocytokines, including information on year of establishment, company size, and location of headquarters.

Chapter 5 provides tabulated profiles of the companies that are engaged in the development of more than three immunocytokines. Each profile features a brief overview of the company, its financial information (if available), product portfolio, recent developments and an informed future outlook.

Chapter 6 provides an insightful analysis of recent developments in this domain. It features list of partnerships that have been inked by stakeholders in this domain, during the period between January 2016 and October 2020, and a brief description of partnership models (such as clinical trial agreements, licensing agreements, mergers and acquisitions, research agreements, research and development agreements, and others). In addition, the report features an analysis of the investments made at various stages of development in companies focused on developing immunocytokines.

Chapter 7 provides a detailed analysis of completed, ongoing, and planned clinical studies of various immunocytokines, highlighting prevalent trends across various relevant parameters, such as trial registration year, phase of development, current trial status, enrolled patient population, study design, leading industry players (in terms of number of trials conducted), study focus, target therapeutic area, and key geographical regions.

Chapter 8 provides an analysis of KOLs in the field of immunocytokines. It features a comprehensive list of principal investigators of different clinical trials, along with information on the affiliated research institutes. The chapter features a schematic world map representation, highlighting the geographical locations of eminent scientists / researchers who are engaged in clinical research in this domain. It also presents a comparative analysis, highlighting those KOLs who have relatively more experience in this domain. The (relative) level of expertise of different KOLs defined by other analysts / industry experts were compared to the results obtained using a proprietary scoring criteria, which was based on parameters, such as number of publications, number of citations, participation in clinical trials, number of affiliations, and strength of professional network (based on information available on LinkedIn).

Chapter 9 features an insightful market forecast analysis, highlighting the likely growth of immunocytokines market, till the year 2030. In order to provide details on the future opportunity, our projections have been segmented on the basis of [A] target disease indications (cervical cancer, cholangiocarcinoma, esophageal cancer, gallbladder cancer, head and neck cancer, melanoma, non-small cell lung cancer, rheumatoid arthritis, and soft tissue sarcoma), [B] routes of administration (intravenous, intratumoral, and subcutaneous), and [C] key geographical regions (US, Canada, Germany, UK, France, Italy, Spain, China, Japan, South Korea, Australia, Brazil, Argentina, Israel, and Turkey). In order to account for future uncertainties and to add robustness to our model, we have provided three market forecast scenarios, namely conservative, base and optimistic scenarios, representing different tracks of the industry’s growth.  

Chapter 10 is a collection of interview transcripts of discussions held with key stakeholders in this market. In this chapter, we have presented a brief overview of the companies and details of our conversations held with Stephen Gillies (President and CEO, Provenance Biopharmaceuticals) and Patrik Kehler (Senior Director Scientific and Business Development, Glycotope).

Chapter 11 summarizes the entire report. It presents the key takeaways and offers our independent opinion on the current market scenario. Further, it captures the evolutionary trends that are likely to determine the future of the immunocytokines market. 

Chapter 12 is an appendix, which provides tabulated data and numbers for all the figures included in the report.

Chapter 13 is an appendix, which contains a list of companies and organizations mentioned in this report.

Table Of Contents

1. PREFACE
1.1. Scope of the Report
1.2. Research Methodology
1.3. Key Questions Answered
1.4. Chapter Outlines

2. EXECUTIVE SUMMARY

3. INTRODUCTION
3.1. Chapter Overview
3.2. Overview of Cytokines
3.2.1. Engineered Cytokines and Immunocytokines
3.3. Challenges Associated with the Development of Immunocytokines
3.4. Future Perspectives

4. CURRENT MARKET LANDSCAPE
4.1. Chapter Overview
4.2. Immunocytokines: Development Pipeline
4.2.1. Analysis by Phase of Development
4.2.2. Analysis by Type of Therapy
4.2.3. Analysis by Type of Cytokine Used
4.2.4. Analysis by Type of Antibody Used
4.2.5. Analysis by Target Disease Indication(s)
4.2.6. Analysis by Route of Administration
4.2.7. Analysis by Phase of Development, Type of Therapy, and Type of Cytokine Used

4.3. Immunocytokines: List of Therapy Developers
4.3.1. Analysis by Year of Establishment
4.3.2. Analysis by Company Size and Geographical Location
4.3.3. Leading Developers: Analysis by Number of Therapies
4.3.4. Regional Analysis of Therapy Developers

5. COMPANY PROFILES
5.1. Chapter Overview
5.2. Genopharm
5.2.1. Company Overview
5.2.2. Immunocytokines Portfolio
5.2.2.1. GNP101
5.2.2.2. GNP201
5.2.2.3. GNP301
5.2.3. Recent Developments and Future Outlook

5.3. ImmunGene
5.3.1. Company Overview
5.3.2. Immunocytokines Portfolio
5.3.2.1. IGN001
5.3.2.2. IGN003
5.3.2.3. IGN004
5.3.2.4. IGN005
5.3.2.5. IGN006
5.3.3. Recent Developments and Future Outlook

5.4. Kanaph Therapeutics
5.4.1. Company Overview
5.4.2. Immunocytokines Portfolio
5.4.2.1. KNP-101
5.4.2.2. KNP-102
5.4.2.3. Cytokine X-Anti-Target A
5.4.2.4. Cytokine X-Anti-Target B
5.4.3. Recent Developments and Future Outlook

5.5. Merck KGaA
5.5.1. Company Overview
5.5.2. Immunocytokines Portfolio
5.5.2.1. EMD 521873
5.5.2.2. M7824
5.5.2.3. M9241
5.5.3. Recent Developments and Future Outlook

5.6. Philogen
5.6.1. Company Overview
5.6.2. Immunocytokines Portfolio
5.6.2.1. Daromun
5.6.2.2. F8IL10
5.6.2.3. F16IL2
5.6.2.4. IL12-L19L19
5.6.2.5. L19IL2
5.6.2.6. L19TNF
5.6.3. Recent Developments and Future Outlook

6. RECENT DEVELOPMENTS
6.1. Chapter Overview
6.2. Recent Developments: Partnerships and Collaborations
6.3. List of Partnerships and Collaborations
6.3.1. Analysis by Year of Partnership
6.3.2. Analysis by Type of Partnership
6.3.3. Analysis by Year of Partnership and Type of Partner
6.3.4. Most Active Players: Analysis by Number of Partnerships
6.3.5. Regional Analysis
6.3.5.1. Intercontinental and Intracontinental Agreements

6.4. Recent Developments: Types of Funding
6.5. Funding and Investment Analysis
6.5.1. Analysis by Number of Funding Instances (Cumulative), 2016-2020
6.5.2. Analysis by Amount Invested
6.5.3. Analysis by Type of Funding
6.5.4. Most Active Players: Analysis by Number of Funding Instances and Amount Invested
6.5.5. Investment Summary by Region

7. CLINICAL TRIAL ANALYSIS
7.1. Chapter Overview
7.2. Scope and Methodology
7.3. Immunocytokines: Clinical Trial Analysis
7.3.1. Analysis by Trial Registration Year
7.3.2. Analysis by Trial Phase
7.3.3. Analysis by Trial Recruitment Status
7.3.4. Analysis by Trial Registration Year and Number of Patients Enrolled
7.3.5. Analysis by Study Design
7.3.6. Analysis by Sponsor / Collaborator
7.3.7. Most Active Players: Analysis by Number of Registered Trials
7.3.8. Emerging Focus Areas
7.3.9. Analysis by Trial Phase and Target Disease Indication
7.3.10. Geographical Analysis by Number of Clinical Trials
7.3.11. Geographical Analysis by Number of Patients Enrolled

8. KEY OPINION LEADERS (KOL) ANALYSIS
8.1. Chapter Overview
8.2. Assumptions and Methodology
8.3. Principal Investigators Involved in Clinical Trials
8.3.1. Analysis by Type of Organization (KOL Affiliation)
8.3.2. Geographical Distribution of KOLs

8.4. Prominent KOLs
8.5. KOL Benchmarking: Roots Analysis’ Assessment versus Third Party (ResearchGate Score)
8.6. Most Active KOLs
8.6.1. KOL Profile: A (Maastricht University)
8.6.2. KOL Profile: B (Centre Léon Bérard)
8.6.3. KOL Profile: C (Eberhard Karls University)
8.6.4. KOL Profile: D (Istituto Clinico Humanitas)
8.6.5. KOL Profile: E (Washington University in St. Louis)

9. MARKET FORECAST AND OPPORTUNITY ANALYSIS
9.1. Chapter Overview
9.2. Forecast Methodology and Key Assumptions
9.3. Global Immunocytokines Market, 2021-2030
9.4. Global Immunocytokines Market, 2021 and 2030: Distribution by Target Disease Indication
9.4.1. Immunocytokines Market for Cervical Cancer, 2021-2030
9.4.2. Immunocytokines Market for Cholangiocarcinoma, 2021-2030
9.4.3. Immunocytokines Market for Esophageal Cancer, 2021-2030
9.4.4. Immunocytokines Market for Gallbladder Cancer, 2021-2030
9.4.5. Immunocytokines Market for Head and Neck Cancer, 2021-2030
9.4.6. Immunocytokines Market for Melanoma, 2021-2030
9.4.7. Immunocytokines Market for Non-small Cell Lung Cancer, 2021-2030
9.4.8. Immunocytokines Market for Rheumatoid Arthritis, 2021-2030
9.4.9. Immunocytokines Market for Soft Tissue Sarcoma, 2021-2030

9.5. Global Immunocytokines Market, 2021 and 2030: Distribution by Route of Administration
9.5.1. Immunocytokines Market for Products Requiring Intravenous Administration, 2021-2030
9.5.2. Immunocytokines Market for Products Requiring Intratumoral Administration, 2021-2030
9.5.3. Immunocytokines Market for Products Requiring Subcutaneous Administration, 2021-2030

9.6. Global Immunocytokines Market, 2021 and 2030: Distribution by Geography
9.6.1. Immunocytokines Market in the US, 2021-2030
9.6.2. Immunocytokines Market in Canada, 2021-2030
9.6.3. Immunocytokines Market in Germany, 2021-2030
9.6.4. Immunocytokines Market in the UK, 2021-2030
9.6.5. Immunocytokines Market in France, 2021-2030
9.6.6. Immunocytokines Market in Italy, 2021-2030
9.6.7. Immunocytokines Market in Spain, 2021-2030
9.6.8. Immunocytokines Market in China, 2021-2030
9.6.9. Immunocytokines Market in Japan, 2021-2030
9.6.10. Immunocytokines Market in South Korea, 2021-2030
9.6.11. Immunocytokines Market in Australia, 2021-2030
9.6.12. Immunocytokines Market in Brazil, 2021-2030
9.6.13. Immunocytokines Market in Argentina, 2021-2030
9.6.14. Immunocytokines Market in Turkey, 2021-2030
9.6.15. Immunocytokines Market in Israel, 2021-2030

9.7. Immunocytokines Market, 2021-2030: Product-wise Sales Forecasts
9.7.1. Daromun
9.7.1.1. Target Patient Population
9.7.1.2. Sales Forecast

9.7.2. F8IL10
9.7.2.1. Target Patient Population
9.7.2.2. Sales Forecast

9.7.3. hu14.18-IL2
9.7.3.1. Target Patient Population
9.7.3.2. Sales Forecast

9.7.4. L19IL2
9.7.4.1. Target Patient Population
9.7.4.2. Sales Forecast

9.7.5. L19TNF
9.7.5.1. Target Patient Population
9.7.5.2. Sales Forecast

9.7.6. M7824
9.7.6.1. Target Patient Population
9.7.6.2. Sales Forecast

9.7.7. RO6874281
9.7.7.1. Target Patient Population
9.7.7.2. Sales Forecast

10. EXECUTIVE INSIGHTS
10.1. Chapter Overview
10.2. Provenance Biopharmaceuticals
10.2.1. Company Snapshot
10.2.2. Interview Transcript: Stephen Gillies, President and Chief Executive Officer

10.3. Glycotope
10.3.1. Company Snapshot
10.3.2. Interview Transcript: Patrik Kehler, Senior Director Scientific and Business Development

11. CONCLUDING REMARKS

12. APPENDIX 1: TABULATED DATA

13. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS

List Of Figures

Figure 3.1 Strategies for the Development of Engineered Cytokines
Figure 4.1 Immunocytokines: Distribution by Phase of Development
Figure 4.2 Immunocytokines: Distribution by Type of Therapy
Figure 4.3 Immunocytokines: Distribution by Type of Cytokine Used
Figure 4.4 Immunocytokines: Distribution by Type of Antibody Used
Figure 4.5 Immunocytokines: Distribution by Target Disease Indication(s)
Figure 4.6 Immunocytokines: Distribution by Phase of Development and Target Disease Indication(s)
Figure 4.7 Immunocytokines: Distribution by Route of Administration
Figure 4.8 Funnel Analysis: Distribution by Phase of Development, Type of Therapy, and Type of Cytokine Used
Figure 4.9 Immunocytokines: Distribution of Developers by Year of Establishment
Figure 4.10 Immunocytokines: Distribution of Developers by Company Size and Geographical Location
Figure 4.11 Leading Developers: Distribution by Number of Therapies
Figure 4.12 World Map Representation: Distribution by Regional Activity
Figure 6.1 Partnerships and Collaborations: Cumulative Year-wise Trend, 2016-2020 (Till October)
Figure 6.2 Partnerships and Collaborations: Distribution by Type of Partnership
Figure 6.3 Partnerships and Collaborations: Distribution by Year and Type of Partnership
Figure 6.4 Partnerships and Collaborations: Distribution by Year and Type of Partner
Figure 6.5 Most Active Players: Distribution by Number of Partnerships
Figure 6.6 Partnerships and Collaborations: Regional Distribution
Figure 6.7 Partnerships and Collaborations: Intercontinental and Intracontinental Agreements
Figure 6.8 Funding and Investments: Cumulative Year-wise Trend, 2016-2020 (Till October)
Figure 6.9 Funding and Investments: Distribution of Amount Invested by Year and Number of Instances, 2016-2020 (USD Million)
Figure 6.10 Funding and Investments: Distribution of Instances by Type of Funding
Figure 6.11 Funding and Investments: Distribution by Year and Type of Funding, 2016-2020 (Till October)
Figure 6.12 Funding and Investments: Distribution of Instances by Total Amount Invested and Type of Funding (USD Million)
Figure 6.13 Most Active Players: Distribution by Number of Funding Instances and Amount Raised (USD Million)
Figure 6.14 Funding and Investments: Regional Distribution by Amount Invested (USD Million)
Figure 7.1 Clinical Trial Analysis: Scope and Methodology
Figure 7.2 Clinical Trial Analysis: Distribution by Trial Status
Figure 7.3 Clinical Trial Analysis: Cumulative Distribution by Trial Registration Year, 2000-2020 (Till November)
Figure 7.4 Clinical Trial Analysis: Distribution by Trial Phase
Figure 7.5 Clinical Trial Analysis: Distribution by Trial Registration Year and Trial Status
Figure 7.6 Clinical Trial Analysis: Geographical Distribution by Trial Registration Year and Trial Recruitment Status
Figure 7.7 Clinical Trial Analysis: Distribution by Trial Registration Year and Enrolled Patient Population
Figure 7.8 Clinical Trial Analysis: Distribution by Study Design
Figure 7.9 Clinical Trial Analysis: Distribution by Sponsor / Collaborator
Figure 7.10 Most Active Players: Distribution by Number of Registered Trials
Figure 7.11 Clinical Trial Analysis: Emerging Focus Area
Figure 7.12 Clinical Trial Analysis: Distribution by Trial Phase and Target Disease Indication
Figure 7.13 Clinical Trial Analysis: Geographical Distribution by Number of Clinical Trials
Figure 7.14 Clinical Trial Analysis: Geographical Distribution by Patients Enrolled
Figure 8.1 KOL Analysis: Distribution by Type of Organization (KOL Affiliation)
Figure 8.2 KOL Analysis: Distribution by Location of Organization (KOL Affiliation)
Figure 8.3 KOL Analysis: Leading Organizations (KOL Affiliation)
Figure 8.4 KOL Analysis: Geographical Distribution of KOLs in North America
Figure 8.5 KOL Analysis: Geographical Distribution of KOLs in Europe
Figure 8.6 KOL Analysis: Geographical Distribution of KOLs in Asia-Pacific and Latin America
Figure 8.7 KOL Analysis: Dot-Plot of KOLs
Figure 8.8 KOL Analysis: Most Prominent KOLs
Figure 8.9 KOL Benchmarking: Roots Analysis’ Assessment versus Third Party (ResearchGate Score)
Figure 9.1 Global Immunocytokines Market, 2021-2030 (USD Million)
Figure 9.2 Global Immunocytokines Market, 2021 and 2030: Distribution by Target Disease Indication (USD Million)
Figure 9.3 Immunocytokines Market for Cervical Cancer, 2021-2030 (USD Million)
Figure 9.4 Immunocytokines Market for Cholangiocarcinoma, 2021-2030 (USD Million)
Figure 9.5 Immunocytokines Market for Esophageal Cancer, 2021-2030 (USD Million)
Figure 9.6 Immunocytokines Market for Gallbladder Cancer, 2021-2030 (USD Million)
Figure 9.7 Immunocytokines Market for Head and Neck Cancer, 2021-2030 (USD Million)
Figure 9.8 Immunocytokines Market for Melanoma, 2021-2030 (USD Million)
Figure 9.9 Immunocytokines Market for Non-small Cell Lung Cancer, 2021-2030 (USD Million)
Figure 9.10 Immunocytokines Market for Rheumatoid Arthritis, 2021-2030 (USD Million)
Figure 9.11 Immunocytokines Market for Soft Tissue Sarcoma, 2021-2030 (USD Million)
Figure 9.12 Global Immunocytokines Market, 2021 and 2030: Distribution by Route of Administration (USD Million)
Figure 9.13 Immunocytokines Market for Products Requiring Intravenous Administration, 2021-2030 (USD Million)
Figure 9.14 Immunocytokines Market for Products Requiring Intratumoral Administration, 2021-2030 (USD Million)
Figure 9.15 Immunocytokines Market for Products Requiring Subcutaneous Administration, 2021-2030 (USD Million)
Figure 9.16 Global Immunocytokines Market, 2021 and 2030: Distribution by Geography (USD Million)
Figure 9.17 Immunocytokines Market in the US, 2021-2030 (USD Million)
Figure 9.18 Immunocytokines Market in Canada, 2021-2030 (USD Million)
Figure 9.19 Immunocytokines Market in Germany, 2021-2030 (USD Million)
Figure 9.20 Immunocytokines Market in the UK, 2021-2030 (USD Million)
Figure 9.21 Immunocytokines Market in France, 2021-2030 (USD Million)
Figure 9.22 Immunocytokines Market in Italy, 2021-2030 (USD Million)
Figure 9.23 Immunocytokines Market in Spain, 2021-2030 (USD Million)
Figure 9.24 Immunocytokines Market in China, 2021-2030 (USD Million)
Figure 9.25 Immunocytokines Market in Japan, 2021-2030 (USD Million)
Figure 9.26 Immunocytokines Market in South Korea, 2021-2030 (USD Million)
Figure 9.27 Immunocytokines Market in Australia, 2021-2030 (USD Million)
Figure 9.28 Immunocytokines Market in Brazil, 2021-2030 (USD Million)
Figure 9.29 Immunocytokines Market in Argentina, 2021-2030 (USD Million)
Figure 9.30 Immunocytokines Market in Turkey, 2021-2030 (USD Million)
Figure 9.31 Immunocytokines Market in Israel, 2021-2030 (USD Million)
Figure 9.32 Daromun: Target Patient Population
Figure 9.33 Daromun Sales Forecast (Till 2030): Base Scenario (USD Million)
Figure 9.34 F8IL10: Target Patient Population
Figure 9.35 F8IL10 Sales Forecast (Till 2030): Base Scenario (USD Million)
Figure 9.36 hu14.18-IL2: Target Patient Population
Figure 9.37 hu14.18-IL2 Sales Forecast (Till 2030): Base Scenario (USD Million)
Figure 9.38 L19IL2: Target Patient Population
Figure 9.39 L19IL2 Sales Forecast (Till 2030): Base Scenario (USD Million)
Figure 9.40 L19TNF: Target Patient Population
Figure 9.41 L19TNF Sales Forecast (Till 2030): Base Scenario (USD Million)
Figure 9.42 M7824: Target Patient Population
Figure 9.43 M7824 Sales Forecast (Till 2030): Base Scenario (USD Million)
Figure 9.44 RO6874281: Target Patient Population
Figure 9.45 RO6874281 Sales Forecast (Till 2030): Base Scenario (USD Million)

List Of Tables

Table 3.1 Types of Cytokines and Their Functions
Table 4.1 Immunocytokines: Development Pipeline
Table 4.2 Immunocytokines: List of Therapy Developers
Table 5.1 Genopharm: Company Snapshot
Table 5.2 Drug Profile: GNP101
Table 5.3 Drug Profile: GNP201
Table 5.4 Drug Profile: GNP301
Table 5.5 Genopharm: Recent Developments and Future Outlook
Table 5.6 ImmunGene: Company Snapshot
Table 5.7 Drug Profile: IGN001
Table 5.8 Drug Profile: IGN003
Table 5.9 Drug Profile: IGN004
Table 5.10 Drug Profile: IGN005
Table 5.11 Drug Profile: IGN006
Table 5.12 ImmunGene: Recent Developments and Future Outlook
Table 5.13 Kanaph Therapeutics: Company Snapshot
Table 5.14 Drug Profile: KNP-101
Table 5.15 Drug Profile: KNP-102
Table 5.16 Drug Profile: Cytokine X-Anti-Target A
Table 5.17 Drug Profile: Cytokine X-Anti-Target B
Table 5.18 Kanaph Therapeutics: Recent Developments and Future Outlook
Table 5.19 Merck KGaA: Company Snapshot
Table 5.20 Drug Profile: EMD 521873
Table 5.21 Drug Profile: M7824
Table 5.22 Drug Profile: M9241
Table 5.23 Merck KGaA: Recent Developments and Future Outlook
Table 5.24 Philogen: Company Snapshot
Table 5.25 Drug Profile: Daromun
Table 5.26 Drug Profile: F8IL10
Table 5.27 Drug Profile: F16IL2
Table 5.28 Drug Profile: IL12-L19L19
Table 5.29 Drug Profile: L19IL2
Table 5.30 Drug Profile: L19TNF
Table 5.31 Philogen: Recent Developments and Future Outlook
Table 6.1 Immunocytokines: List of Partnerships and Collaborations, 2016-2020 (Till October)
Table 6.2 Immunocytokines: List of Funding and Investments, 2016-2020 (Till October)
Table 8.1 Immunocytokines: List of Principal Investigators
Table 8.2 KOL Profile: A (Maastricht University)
Table 8.3 KOL Profile: B (CLCC Léon Bérard)
Table 8.4 KOL Profile: C (Eberhard Karls University)
Table 8.5 KOL Profile: D (Istituto Clinico Humanitas)
Table 8.6 KOL Profile: E (Washington University in St. Louis)
Table 10.1 Provenance Biopharmaceuticals: Company Snapshot
Table 10.2 Glycotope: Company Snapshot
Table 12.1 Immunocytokines: Distribution by Phase of Development
Table 12.2 Immunocytokines: Distribution by Type of Therapy
Table 12.3 Immunocytokines: Distribution by Type of Cytokine Used
Table 12.4 Immunocytokines: Distribution by Type of Antibody Used
Table 12.5 Immunocytokines: Distribution by Target Disease Indication(s)
Table 12.6 Immunocytokines: Distribution by Route of Administration
Table 12.7 Immunocytokines: Distribution of Developers by Year of Establishment
Table 12.8 Immunocytokines: Distribution of Developers by Company Size and Geographical Location
Table 12.9 Leading Developers: Distribution by Number of Therapies
Table 12.10 Partnerships and Collaborations: Cumulative Year-wise Trend, 2016-2020 (Till October)
Table 12.11 Partnerships and Collaborations: Distribution by Type of Partnership
Table 12.12 Partnerships and Collaborations: Distribution by Year and Type of Partnership
Table 12.13 Partnerships and Collaborations: Distribution by Year and Type of Partner
Table 12.14 Most Active Players: Distribution by Number of Partnerships
Table 12.15 Partnerships and Collaborations: Regional Distribution
Table 12.16 Funding and Investments: Cumulative Year-wise Trend, 2016-2020 (Till October)
Table 12.17 Funding and Investments: Distribution of Amount Invested by Year and Number of Instances, 2016-2020 (USD Million)
Table 12.18 Funding and Investments: Distribution of Instances by Type of Funding
Table 12.19 Funding and Investments: Distribution by Year and Type of Funding, 2016-2020 (Till October)
Table 12.20 Funding and Investments: Distribution of Instances by Total Amount Invested and Type of Funding (USD Million)
Table 12.21 Most Active Players: Distribution by Number of Funding Instances and Amount Raised (USD Million)
Table 12.22 Clinical Trial Analysis: Distribution by Trial Status
Table 12.23 Clinical Trial Analysis: Cumulative Distribution by Trial Registration Year, 2000-2020 (Till November)
Table 12.24 Clinical Trial Analysis: Distribution by Trial Phase
Table 12.25 Clinical Trial Analysis: Distribution by Trial Registration Year and Trial Status
Table 12.26 Clinical Trial Analysis: Distribution by Trial Registration Year and Enrolled Patient Population
Table 12.27 Clinical Trial Analysis: Distribution by Study Design
Table 12.28 Leading Trial Sponsors: Distribution by Number of Registered Trials
Table 12.29 Most Active Players: Distribution by Number of Registered Trials
Table 12.30 Clinical Trial Analysis: Geographical Distribution by Number of Clinical Trials
Table 12.31 KOL Analysis: Distribution by Type of Organization (KOL Affiliation)
Table 12.32 KOL Analysis: Distribution by Location of Organization (KOL Affiliation)
Table 12.33 KOL Analysis: Leading Organizations (KOL Affiliation)
Table 12.34 KOL Benchmarking: Most Prominent KOLs
Table 12.35 KOL Analysis: Roots Analysis’ Assessment versus Third Party (ResearchGate Score)
Table 12.36 Global Immunocytokines Market, Conservative, Base, and Optimistic Scenarios, 2021-2030 (USD Million)
Table 12.37 Global Immunocytokines Market, 2021 and 2030: Distribution by Target Disease Indication (USD Million)
Table 12.38 Immunocytokines Market for Cervical Cancer, Conservative, Base, and Optimistic Scenarios, 2021-2030 (USD Million)
Table 12.39 Immunocytokines Market for Cholangiocarcinoma, Conservative, Base, and Optimistic Scenarios, 2021-2030 (USD Million)
Table 12.40 Immunocytokines Market for Esophageal Cancer, Conservative, Base, and Optimistic Scenarios, 2021-2030 (USD Million)
Table 12.41 Immunocytokines Market for Gallbladder Cancer, Conservative, Base, and Optimistic Scenarios, 2021-2030 (USD Million)
Table 12.42 Immunocytokines Market for Head and Neck Cancer, Conservative, Base, and Optimistic Scenarios, 2021-2030 (USD Million)
Table 12.43 Immunocytokines Market for Melanoma, Conservative, Base, and Optimistic Scenarios, 2021-2030 (USD Million)
Table 12.44 Immunocytokines Market for Non-small Cell Lung Cancer, Conservative, Base, and Optimistic Scenarios, 2021-2030 (USD Million)
Table 12.45 Immunocytokines Market for Rheumatoid Arthritis, Conservative, Base, and Optimistic Scenarios, 2021-2030 (USD Million)
Table 12.46 Immunocytokines Market for Soft Tissue Sarcoma, Conservative, Base, and Optimistic Scenarios, 2021-2030 (USD Million)
Table 12.47 Global Immunocytokines Market, 2021 and 2030: Distribution by Route of Administration (USD Million)
Table 12.48 Immunocytokines Market for Products Requiring Intravenous Administration, Conservative, Base, and Optimistic Scenarios, 2021-2030 (USD Million)
Table 12.49 Immunocytokines Market for Product Requiring Intratumoral Administration, Conservative, Base, and Optimistic Scenarios, 2021-2030 (USD Million)
Table 12.50 Immunocytokines Market for Products Requiring Subcutaneous Administration, Conservative, Base, and Optimistic Scenarios, 2021-2030 (USD Million)
Table 12.51 Global Immunocytokines Market, 2021 and 2030: Distribution by Geography (USD Million)
Table 12.52 Immunocytokines Market in the US, Conservative, Base, and Optimistic Scenarios, 2021-2030 (USD Million)
Table 12.53 Immunocytokines Market in Canada, Conservative, Base, and Optimistic Scenarios, 2021-2030 (USD Million)
Table 12.54 Immunocytokines Market in Germany, Conservative, Base, and Optimistic Scenarios, 2021-2030 (USD Million)
Table 12.55 Immunocytokines Market in the UK, Conservative, Base, and Optimistic Scenarios, 2021-2030 (USD Million)
Table 12.56 Immunocytokines Market in France, Conservative, Base, and Optimistic Scenarios, 2021-2030 (USD Million)
Table 12.57 Immunocytokines Market in Italy, Conservative, Base, and Optimistic Scenarios, 2021-2030 (USD Million)
Table 12.58 Immunocytokines Market in Spain, Conservative, Base, and Optimistic Scenarios, 2021-2030 (USD Million)
Table 12.59 Immunocytokines Market in China, Conservative, Base, and Optimistic Scenarios, 2021-2030 (USD Million)
Table 12.60 Immunocytokines Market in Japan, Conservative, Base, and Optimistic Scenarios, 2021-2030 (USD Million)
Table 12.61 Immunocytokines Market in South Korea, Conservative, Base, and Optimistic Scenarios, 2021-2030 (USD Million)
Table 12.62 Immunocytokines Market in Australia, Conservative, Base, and Optimistic Scenarios, 2021-2030 (USD Million)
Table 12.63 Immunocytokines Market in Brazil, Conservative, Base, and Optimistic Scenarios, 2021-2030 (USD Million)
Table 12.64 Immunocytokines Market in Argentina, Conservative, Base, and Optimistic Scenarios, 2021-2030 (USD Million)
Table 12.65 Immunocytokines Market in Turkey, Conservative, Base, and Optimistic Scenarios, 2021-2030 (USD Million)
Table 12.66 Immunocytokines Market in Israel, Conservative, Base, and Optimistic Scenarios, 2021-2030 (USD Million)
Table 12.67 Daromun Sales Forecast (Till 2030): Conservative, Base, and Optimistic Scenarios, (USD Million)
Table 12.68 F8IL10 Sales Forecast (Till 2030): Conservative, Base, and Optimistic Scenarios, (USD Million)
Table 12.69 hu14.18-IL2 Sales Forecast (Till 2030): Conservative, Base, and Optimistic Scenarios, (USD Million)
Table 12.70 L19IL2 Sales Forecast (Till 2030): Conservative, Base, and Optimistic Scenarios, (USD Million)
Table 12.71 L19TNF Sales Forecast (Till 2030): Conservative, Base, and Optimistic Scenarios, (USD Million)
Table 12.72 M7824 Sales Forecast (Till 2030): Conservative, Base, and Optimistic Scenarios, (USD Million)
Table 12.73 RO6874281 Sales Forecast (Till 2030): Conservative, Base, and Optimistic Scenarios, (USD Million)

List of Companies

The following companies and organizations have been mentioned in the report.

  1. AbbVie
  2. Abion
  3. Agilent Technologies
  4. Alopexx Oncology
  5. Anglia Ruskin University
  6. Antisoma Research
  7. Asan Medical Center
  8. Assistance Publique – Hôpitaux de Marseille
  9.  Augusta University
  10. Austin Health
  11. Bács-Kiskun County Hospital
  12. Baptist Health
  13. Barts Health NHS Trust
  14. Boston Children's Hospital
  15. California Cancer Associates for Research and Excellence
  16. Calvary Central Districts Hospital
  17. Catalan Institute of Oncology
  18. Celgene
  19. Center Georges - François Leclerc
  20. Centre Hospitalier Universitaire de Liège
  21. Centre Hospitalier Universitaire de Toulouse
  22. Centre Léon Bérard
  23. Chang Gung Memorial Hospital
  24. Charles University
  25. China Medical University Hospital
  26. Chongqing University Cancer Hospital
  27. City of Hope National Medical Center
  28. Clínica Universidad de Navarra
  29. Cliniques universitaires Saint-Luc
  30. Columbia University
  31. Columbia University Irving Medical Center
  32. Compassionate Care Research Management Group
  33. Comprehensive Cancer Centers
  34. Cytune Pharma
  35. Dana-Farber Cancer Institute
  36. Eberhard Karls Universität Tübingen
  37. EMD Serono
  38. F. Hoffmann-La Roche
  39. FirstHealth of the Carolinas
  40. Florida Cancer Specialists & Research Institute
  41. Fondazione IRCCS- Istituto Nazionale dei Tumori
  42. Fox Chase Cancer Center
  43. Fudan University
  44. Genopharm
  45. GI Innovation
  46. Gilead Sciences
  47. Glycotope
  48.  GZA Ziekenhuizen
  49. H. Lee Moffitt Cancer Center & Research Institute
  50. Helios Klinikum Bad Saarow
  51. Henry Ford Health System
  52. Highlands Oncology Group
  53. Hôpital Cochin
  54. Hospices Civils de Lyon
  55. Hospital Clínic de Barcelona
  56. Hospital Universitario HM Sanchinarro
  57. Hospital Universitario Madrid Sanchinarro
  58. Hospital Universitario Virgen del Rocío
  59. Hospital Universitario Virgen Macarena
  60. Icahn School of Medicine at Mount Sinai
  61. IGM Biosciences
  62. ImmunGene
  63. Immunomedics
  64. Insitute de Cancérologie de I’Quest 
  65. Institut Bergonie
  66. Institut Català d'Oncologia
  67. Gustave Roussy
  68. Institut Jean Godinot
  69. Instituto do Câncer de São Paulo
  70. IRCCS Istituto Clinico Humanitas
  71. IRCCS Ospedale San Raffaele
  72. Istituto Europeo di Oncologia
  73. Istituto Oncologico Veneto
  74. IRCCS Istituto Romagnolo per lo Studio dei Tumori "Dino Amadori" - IRST
  75. Istituto Toscano Tumori
  76. Janssen Biotech
  77. Jeroen Bosch Ziekenhuis
  78. Kadmon
  79. Kanaph Therapeutics
  80. Kindai University
  81. King's College London
  82. Kymab
  83. Maastricht University
  84. Mayo Clinic
  85. Memorial Sloan Kettering Cancer Center
  86. Merck
  87. Merck KGaA
  88. Methodist Health System
  89. Mount Sinai Medical Center
  90. Narodowy Instytut Onkologii im. Marii SkÅ‚odowskiej-Curie – PaÅ„stwowy Instytut Badawczy
  91. National Cancer Institute
  92. National Cheng Kung University Hospital
  93. National Taiwan University Hospital
  94. NEXT Oncology
  95. Novartis
  96. Oklahoma City University
  97. Olivia Newton-John Cancer Research Institute
  98. OSE Immunotherapeutics
  99. Peter MacCallum Cancer Centre
  100. Philochem
  101. Philogen
  102. Policlinico Universitario Agostino Gemelli
  103. Provenance Biopharmaceuticals
  104. Ronald Reagan UCLA Medical Center
  105. Roswell Park Comprehensive Cancer Center
  106. Samsung Medical Center
  107. Sarah Cannon Research Institute
  108. Sarcoma Oncology Center
  109. Seoul National University Bundang Hospital
  110. Severance Hospital
  111. Shenogen Pharma Group
  112. Sidney Kimmel Comprehensive Cancer Center
  113. Simcere
  114. SOTIO
  115. Spectrum Pharmaceuticals
  116. St Vincent's Hospital Melbourne
  117. St. Joseph's Hospital and Medical Center
  118. START Center for Cancer Care
  119. Sun Yat-sen University Cancer Center
  120. Taipei Veterans General Hospital
  121. TCRCure Biopharma
  122. Texas Oncology
  123. The Catholic University of Korea
  124. The Center for Cancer and Blood Disorders
  125. The University of Sydney
  126. The University of Texas MD Anderson Cancer Center
  127. The University of Texas Southwestern Medical Center
  128. UC Davis Comprehensive Cancer Center
  129. Università di Pisa
  130. Universitair Ziekenhuis Antwerpen
  131. Universitair Ziekenhuis Brussel
  132. Universitair Ziekenhuis Gent
  133. Universitair Ziekenhuis Leuven
  134. Universitätsklinikum Münster
  135. University of California, Irvine Medical Center
  136. University of Chicago Medical Center
  137. University of Cincinnati
  138. University of Colorado Health
  139. University of Kansas Medical Center Research Institute
  140. University of Maryland
  141. University of Pittsburgh Medical Center
  142. University of Western Australia
  143. Vall d'Hebron Institute of Oncology
  144. Valor Biotherapeutics
  145. Vanderbilt University Medical Center
  146. Virginia Cancer Specialists
  147. Washington University in St. Louis
  148. Xinqiao Hospital
  149. Y-Biologics

PRICING DETAILS

USD 5,899

This license grants the right of use of the purchased report to a single recipient only (normally the person who buys the report). You may access the material on your computer, as and when required, for your own personal use. You may also print read more

This license grants the right of use of the purchased report by the employees of a business unit at a particular site/office location. The report may be accessed on the computer of any employee within the business unit. You may also print multiple read more

This license grants the right of use of the purchased report by a department / team of individuals (up to 12) in a particular organization. The license does not limit the use to a particular site / office location. The report may be accessed on the computer read more

This license entitles the buyer of the report to share, distribute the report (either full or in part) with other employees of the same firm/enterprise. The report may be accessed by any employee of the enterprise and there is no limit on the read more

Discounts available for multiple report purchases
sales@rootsanalysis.com

This site uses cookies for better browsing experienceAccept

Copyright © 2023 Roots Analysis. All Rights Reserved.